Search with one or more keywords

This page gives you access to all the studies carried out by French researchers, identified on Covid-19.

To view other resources related to Covid-19, click here.

xml
XML

Export to XML

Please choose the format :

XML
XML-DDI
pdf
PDF

Export to PDF

Which version do you want to export ?

Download full content
Download light content
csv
CSV (Excel)

Export to CSV

What sections do you want to export ?

Métadonnées
Identification
General Aspects
Scientific investigator(s) (Contact)
Collaborations
Funding
Governance of the database
Additional contact
Type of database
Database objective
Population type
Dates
Size of the database
Data
Procedures
Promotion
Access
Select all | Invert selection | No selection
Export to CSV

ARCHIVES : 309 forms

Sorting of results :

CALIPSO - Cross-sectional study on fish, seafood and Omega-3 consumption in French coastal populations

Head : Bemrah Nawel, Risk Assessment Department
Sirot Véronique
Leblanc Jean-Charles
Volatier Jean-Luc

Version 1
Voir
View
Overview

271

Last update : 10/20/2017

ARCHIVE

CALIPSO - Cross-sectional study on fish, seafood and Omega-3 consumption in French coastal populations

Head : Bemrah Nawel, Risk Assessment Department
Sirot Véronique
Leblanc Jean-Charles
Volatier Jean-Luc

Main objective

Provide data on seafood consumption in a French coastal population and look at n-3 polyunsaturated fatty acid intake

Inclusion criteria

Person over 18 living in a coastal area and consuming fish and/or seafood at least 2 times per week

Last update : 10/20/2017

Voir
View

KBP-CPHG - Cohort of Patients with Primary Bronchial Lung Cancer

Head : Grivaux Michel, Pulmonology

Version 1
Voir
View
Overview

272

Last update : 01/01/2020

ARCHIVE

KBP-CPHG - Cohort of Patients with Primary Bronchial Lung Cancer

Head : Grivaux Michel, Pulmonology

Main objective

The main aim is to study patient mortality at 5 years and risk factors. Secondary aims are:
– to describe the characteristics in this patient population, their cancer and treatment methods;
– to estimate the survival rate at 1, 4 and 5 years;
– to compare data obtained with data from the KBP-2000-CPHG study (same study type, centre and patient recruitment methods, patient inclusion criteria and several common items in both questionnaires).

Inclusion criteria

All patients with histological and cytological BPC diagnosed between 01 January and 31 December 2000 and 01 January and 31 December 2010. Patients monitored by the pulmonology unit in one of the general hospitals centres (GHC).

Last update : 01/01/2020

Voir
View

- Cross-sectional study in the general population: mental health in 4 French regions (Ile-de-France, Lorraine, Rhône-Alpes, Normandy)

Head : Kovess-Masféty Viviane, METIS Department, Epidemiology and biostatistics for decision-making in public health / Health Process and Psychopathology Laboratory (EA 4057)
Fermanian Christophe, Métis

Version 1
Voir
View
Overview

273

Last update : 10/20/2017

ARCHIVE

- Cross-sectional study in the general population: mental health in 4 French regions (Ile-de-France, Lorraine, Rhône-Alpes, Normandy)

Head : Kovess-Masféty Viviane, METIS Department, Epidemiology and biostatistics for decision-making in public health / Health Process and Psychopathology Laboratory (EA 4057)
Fermanian Christophe, Métis

Main objective

Provide indicators of mental health needs based on social indicators to enable better planning based on the needs of a "population pool"

Inclusion criteria

Subjects drawn randomly

Last update : 10/20/2017

Voir
View

ETNA - Field Study of innovative therapies in oncology: bevacizumab (Avastin®), an anti-angiogenic agent

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Version 3
Voir
View
Overview

274

Last update : 07/22/2015

ETNA - Field Study of innovative therapies in oncology: bevacizumab (Avastin®), an anti-angiogenic agent

Head : Fourrier-Reglat Annie, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen
Moore Nicholas, Service de Pharmacologie, CIC-P 0005-INSERM U657- Université Bordeaux Segalen

Main objective

The main objectives of the study were to describe the population of patients with metastatic colorectal cancer and treated in real-life with first-line bevacizumab, describe the conditions of use of this drug, evaluate the safety of treatments and effectiveness in terms of response and overall and progression free survival at 12 and 24 months follow up.

Inclusion criteria

Patient with metastatic colorectal cancer who initiated bevacizumab in first-line palliative treatment regardless of the associated cancer treatment between 1 January 2006 and 31 December 2007 (whether or not the treatment is continued); Interval between adjuvant chemotherapy for primary cancer and the initiation of bevacizumab ≥6 months; Absence of chemotherapy for metastases before initiation of bevacizumab; Patient had not previously treated with bevacizumab, including during a clinical trial or Temporary Authorisation of Use; Patient with a prescribing physician or their head of department who agreed to participate in the study; Patient not participating in a clinical trial (Huriet-Sérusclat), unless it has a standard treatment (control arm) in an open-label Phase III study (bevacizumab known); Patient not objecting to the data collection.

Last update : 07/22/2015

Voir
View

OPALE - Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Head : Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Version 2
Voir
View
Overview

275

Last update : 02/03/2012

OPALE - Survey of the therapeutic management of rheumatoid arthritis in France in 2006

Head : Bregman Bruno, Bristol-Myers Squibb
Schmidely Nathalie, Bristol-Myers Squibb

Main objective

Describe the therapeutic pratice used by French rhumatologists in patients suffering from rheumatoid arthritis patients, and describe the treatment patterns used, in a general manner and according to the patients' and disease characteristics.

Inclusion criteria

Register Part: M/F >=18 years, with a midl to severe rheumatoid arthritis currently treated or not treated with either symptomatic agents or DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological), seen in rheumatology clinic visit.
Detailed Study Part: patients eligible for the register part, currently treated or initiating a first DMARD (disease-modifying anti-rheumatism drug treatment) (biological or non-biological) at the time of inclusion in the study

Last update : 02/03/2012

Voir
View

THDA/TPL - Étude transversale sur les troubles d'hyperactivité avec déficit de l'attention (THDA) chez les adolescents souffrant d'un trouble limite de la personnalité (TPL)

Head : Falissard Bruno, Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Revah-Levy Anne, Centre de Soins Psychothérapeutiques de Transition pour Adolescents
Speranza Mario , Service de Pédopsychiatrie.
Cortese Samuele
Pham-Scottez Alexandra
Corcos Maurice , Département de Psychiatrie de l'Adolescent et du Jeune Adulte

Version 1
Voir
View
Overview

276

Last update : 12/01/2017

ARCHIVE

THDA/TPL - Étude transversale sur les troubles d'hyperactivité avec déficit de l'attention (THDA) chez les adolescents souffrant d'un trouble limite de la personnalité (TPL)

Head : Falissard Bruno, Inserm U1018 - Centre de Recherche en Épidémiologie et Santé des Populations Équipe: Genre, Santé sexuelle et Reproductive
Revah-Levy Anne, Centre de Soins Psychothérapeutiques de Transition pour Adolescents
Speranza Mario , Service de Pédopsychiatrie.
Cortese Samuele
Pham-Scottez Alexandra
Corcos Maurice , Département de Psychiatrie de l'Adolescent et du Jeune Adulte

Main objective

1) évaluer la prévalence passée et actuelle de la comorbidité du diagnostic THDA/TPL et son impact sur la présentation clinique de trouble de la personnalité limite chez les adolescents
2) déterminer le type d'impulsivité qui caractérise spécifiquement les adolescents avec THDA/TPL.

Inclusion criteria

Patients de cinq centres universitaires psychiatriques en France, en Belgique et en Suisse âgés de 15 à 19 ans avec un diagnostic de trouble limite de la personnalité selon les critères du DSM-IV.
Les critères d'exclusion: diagnostic de schizophrénie ou de maladie chronique et/ou médicale grave impliquant le pronostic vital.

Last update : 12/01/2017

Voir
View

Please wait...

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05